Spots Global Cancer Trial Database for Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
Official Title: A Two Arm Phase II Study Comparing Docetaxel/Cisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage IIIA-Multiple cN2 or IIIB)
Study ID: NCT00174772
Conditions
Study Description
Brief Summary: Primary Objective: * To evaluate the toxicity/safety profile of docetaxel/cisplatin induction therapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by consolidation docetaxel/cisplatin in patients with locally advanced unresectable NSCLC (stage IIIA- multiple cN2 or IIIB). Secondary Objective: * To estimate efficacy parameters in overall response rate, progression free survival and 1 year survival for each of the two above mentioned arms.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Sanofi-Aventis Administrative Office, Diegem, , Belgium
Sanofi-Aventis Administrative Office, Helsinki, , Finland
Sanofi-Aventis Administrative Office, Paris, , France
Sanofi-Aventis Administrative Office, Milan, , Italy
Sanofi-Aventis Administrative Office, Gouda, , Netherlands
Sanofi-Aventis Administrative Office, Barcelona, , Spain
Sanofi-Aventis Administrative Office, Istanbul, , Turkey
Sanofi-Aventis Administrative Office, Guilford, , United Kingdom
Contact Details
Name: Jean-Philippe Aussel
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
